All In Biotech

Drug Trial Radar · NCT05266105

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Actual

Start

Dec 10, 2021

Primary completion

Mar 2026

Study completion Mar 2026

Sponsor

Lead sponsor
Olema Oncology, Inc.Industry
Sponsor type
Industry
Collaborators
Pfizer
First posted
Mar 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, Phase 1b dose escalation and expansion study to determine the maximum tolerated dose (MTD) of OP-1250 in combination with palbociclib (Ibrance®️, Pfizer Inc.). Purpose of study is to evaluate the safety and pharmacokinetic (PK) profile, and estimate the preliminary anti-tumor activity of the combination in adult subjects with hormone receptor-positive (ER+ / HER2-) advanced or metastatic breast cancer (MBC).

Conditions

  • Breast Cancer

Interventions

  • PalazestrantDrug

    Complete Estrogen Receptor Antagonist

  • PalbociclibDrug

    Palbociclib is an approved CDK 4/6 Inhibitor drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting ToxicitiesTime frame: From Cycle 1 Day 1 through C1 Day 28
  2. Characterization and Incidence in Adverse Events and Serious Adverse EventsTime frame: From initial inform consent date through 30 days post last dose
  3. Plasma levels of OP-1250 and PalbociclibTime frame: Up to 9 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Waratah, New South Wales, Australia

  • Clinical Trial Site

    Westmead, New South Wales, Australia

  • Clinical Trial Site

    South Brisbane, Queensland, Australia

  • Clinical Trial Site

    Southport, Queensland, Australia

  • Clinical Trial Site

    Clayton, Victoria, Australia

  • Clinical Trial Site

    Frankston, Victoria, Australia

  • Clinical Trial Site

    Geelong, Victoria, Australia

  • Clinical Trial Site

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.